var data={"title":"Acute myeloid leukemia: Treatment and outcomes in older adults","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Acute myeloid leukemia: Treatment and outcomes in older adults</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/contributors\" class=\"contributor contributor_credentials\">Richard A Larson, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/contributors\" class=\"contributor contributor_credentials\">Bob Lowenberg, MD, PhD</a></dd><dd><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/contributors\" class=\"contributor contributor_credentials\">Kenneth E Schmader, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/contributors\" class=\"contributor contributor_credentials\">Alan G Rosmarin, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Mar 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 27, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Management of acute myeloid leukemia (AML) in older adults (&ge;60 years old) differs from treatment of younger adults. Compared with younger patients with AML, older patients are more often undertreated, suffer more treatment-related toxicity, and have inferior clinical outcomes.</p><p>This topic will discuss treatment and outcomes of AML in older adults.</p><p>The following topics are presented separately:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Overview of AML (see <a href=\"topic.htm?path=overview-of-acute-myeloid-leukemia-in-adults\" class=\"medical medical_review\">&quot;Overview of acute myeloid leukemia in adults&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pretreatment evaluation and prognosis of AML in older adults (see <a href=\"topic.htm?path=pretreatment-evaluation-and-prognosis-of-acute-myeloid-leukemia-in-older-adults\" class=\"medical medical_review\">&quot;Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment of younger adults with AML (see <a href=\"topic.htm?path=induction-therapy-for-acute-myeloid-leukemia-in-younger-adults\" class=\"medical medical_review\">&quot;Induction therapy for acute myeloid leukemia in younger adults&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment of adults of any age with therapy-related AML (see <a href=\"topic.htm?path=therapy-related-myeloid-neoplasms-acute-myeloid-leukemia-and-myelodysplastic-syndrome\" class=\"medical medical_review\">&quot;Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Special considerations for the use of chemotherapy in older patients (see <a href=\"topic.htm?path=systemic-chemotherapy-for-cancer-in-elderly-persons\" class=\"medical medical_review\">&quot;Systemic chemotherapy for cancer in elderly persons&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment of adults of any age with acute promyelocytic leukemia with t(15;17) (formerly known as FAB M3 AML) (see <a href=\"topic.htm?path=initial-treatment-of-acute-promyelocytic-leukemia-in-adults\" class=\"medical medical_review\">&quot;Initial treatment of acute promyelocytic leukemia in adults&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H3665949846\"><span class=\"h1\">DEFINITIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Older adults</strong> &ndash; Older adults are defined here (and in most clinical studies of AML) as &ge;60 years old. Because the median age of presentation with AML is approximately 70 years, AML is primarily a disease of older patients [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Acute myeloid leukemia (AML)</strong> &ndash; Criteria for the diagnosis and classification of AML are discussed separately. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-acute-myeloid-leukemia#H20\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Other definitions</strong> &ndash; Descriptions of remission induction, consolidation, maintenance therapy; response definitions and criteria; and other aspects of AML management are discussed separately. (See <a href=\"topic.htm?path=overview-of-acute-myeloid-leukemia-in-adults\" class=\"medical medical_review\">&quot;Overview of acute myeloid leukemia in adults&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H266976324\"><span class=\"h1\">DISTINCTIVE ASPECTS OF AML IN OLDER ADULTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Age-associated physiology, comorbid illnesses, and biologic aspects of leukemic cells in older adults affect the ability of older patients to tolerate treatment and contribute to worse outcomes.</p><p>Compared with younger patients with AML, older patients have:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Age-associated declines in cardiac, pulmonary, renal, gastrointestinal, hematopoietic, neuropsychiatric, and metabolic functions [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/3\" class=\"abstract_t\">3</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>More numerous and severe comorbidities [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/4,5\" class=\"abstract_t\">4,5</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Leukemia cells that are more likely to present adverse biological features, including unfavorable cytogenetic findings, intrinsic drug resistance, and antecedent hematopoietic disorders [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/6,7\" class=\"abstract_t\">6,7</a>]. (See <a href=\"topic.htm?path=pretreatment-evaluation-and-prognosis-of-acute-myeloid-leukemia-in-older-adults#H6273191\" class=\"medical medical_review\">&quot;Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults&quot;, section on 'Prognosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lower rates of treatment and enrollment in therapeutic clinical trials [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"headingAnchor\" id=\"H1487970949\"><span class=\"h1\">GOALS OF CARE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Goals of care for the older patient with AML should be established in discussions between the patient and clinicians.</p><p>Medical fitness, age, individual goals and fears, and prognostic features of the leukemic cells are factors in establishing the goals of care. Assessment of medical fitness and prognostic features of AML are discussed below and separately. (See <a href=\"topic.htm?path=pretreatment-evaluation-and-prognosis-of-acute-myeloid-leukemia-in-older-adults\" class=\"medical medical_review\">&quot;Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults&quot;</a> and <a href=\"#H2593273779\" class=\"local\">'Determination of medical fitness'</a> below and <a href=\"topic.htm?path=prognosis-of-acute-myeloid-leukemia\" class=\"medical medical_review\">&quot;Prognosis of acute myeloid leukemia&quot;</a>.)</p><p>Our approach follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For most medically fit patients and for many patients of intermediate medical fitness, the goal is to achieve long-term survival with the possibility of cure.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For medically frail patients and for some patients of intermediate fitness, the goals are to prolong life, alleviate symptoms, <span class=\"nowrap\">and/or</span> improve quality of life.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For some patients with extreme debility, advanced age, or severe comorbid medical conditions, treatment aimed at modifying the disease course may be inadvisable, and supportive care is offered.</p><p/><p>Clinicians should discuss the goals of care with the patient and loved ones at the time of diagnosis and periodically through the course of the disease. Discussions should acknowledge that for most patients, AML will be a life-ending disease. Many patients overestimate their long-term prognosis and chance for cure, and don't recall being offered more than one treatment [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/8,9\" class=\"abstract_t\">8,9</a>]. Personal treatment goals, including the degree of &quot;aggressiveness,&quot; may have greater influence on management decisions than a defined therapeutic algorithm. Mutual understanding between the patient, family members, and practitioners will facilitate conversations regarding goals of care, selection of therapy, health care proxies, do-not-resuscitate directives, and end-of-life decisions.</p><p class=\"headingAnchor\" id=\"H2593273779\"><span class=\"h1\">DETERMINATION OF MEDICAL FITNESS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Medical fitness of the older adult is the primary determinant of management of AML and informs decisions regarding goals of care, initial therapy, and post-remission management. The disease burden itself can contribute to lack of fitness, so that attainment of an initial remission may enhance the patient&rsquo;s ability to tolerate and benefit from additional intensive treatment.</p><p>Medical fitness of the older patient with AML includes evaluation of:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>ECOG (Eastern Cooperative Oncology Group) performance status (PS) (<a href=\"image.htm?imageKey=HEME%2F72901\" class=\"graphic graphic_table graphicRef72901 \">table 1</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Physiologic fitness (eg, comorbid conditions, activities of daily living, physical performance tests, cognition), as measured by:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Charlson comorbidity index (CCI) (<a href=\"image.htm?imageKey=HEME%2F65323\" class=\"graphic graphic_table graphicRef65323 \">table 2</a>)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Short Physical Performance Battery (SPPB; <a href=\"http://geriatrictoolkit.missouri.edu/SPPB-Score-Tool.pdf&amp;token=HlGFykY2pIYPqZUdoKw6koroztLJorBB3HjUNdYtKxclCm0iA4hzESJdTstTv9Ey4ATbw9uaQx4q+A51ewd+Lw==&amp;TOPIC_ID=4530\" target=\"_blank\" class=\"external\">http://geriatrictoolkit.missouri.edu/SPPB-Score-Tool.pdf</a>) [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/10\" class=\"abstract_t\">10</a>]</p><p/><p>Comprehensive geriatric assessment tools and geriatric consultation may aid assessment of the medical fitness of the older patient with AML [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/11,12\" class=\"abstract_t\">11,12</a>]. Detailed assessment of medical fitness in the older patient with AML and its impact on clinical outcomes are presented separately. (See <a href=\"topic.htm?path=pretreatment-evaluation-and-prognosis-of-acute-myeloid-leukemia-in-older-adults\" class=\"medical medical_review\">&quot;Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults&quot;</a>.)</p><p>Our approach for categorizing medical fitness of older patients with AML is as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Medically fit</strong> (both of the following):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>ECOG PS 0 or 1</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>CCI 0</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Intermediate medical fitness</strong> (any of the following):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>ECOG PS 2</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>SPPB score 9</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>CCI 1</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Medical frailty</strong> (any of the following):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>ECOG PS &ge;3</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>SPPB score &lt;9</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>CCI &gt;1</p><p/><p>Details regarding management of AML for each category of medical fitness are provided in the sections of this topic below. (See <a href=\"#H1564444133\" class=\"local\">'Selection of initial therapy'</a> below.)</p><p class=\"headingAnchor\" id=\"H1687713850\"><span class=\"h1\">OUR APPROACH TO INITIAL THERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no optimal treatment for all older patients with AML. Our preferred approach for management is enrollment on a clinical trial. Outside the context of a clinical trial, optimal outcomes result from proper selection of treatment, as described below.</p><p class=\"headingAnchor\" id=\"H2191324414\"><span class=\"h2\">Emergency management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with cardiac, respiratory, or other organ system decompensation, and those with white blood cell (WBC) count <span class=\"nowrap\">&gt;50,000/microL,</span> should undergo urgent evaluation and management.</p><p>Further discussion of AML complications and management are discussed separately. (See <a href=\"topic.htm?path=hyperleukocytosis-and-leukostasis-in-hematologic-malignancies#H7\" class=\"medical medical_review\">&quot;Hyperleukocytosis and leukostasis in hematologic malignancies&quot;, section on 'Management'</a> and <a href=\"topic.htm?path=overview-of-the-complications-of-acute-myeloid-leukemia\" class=\"medical medical_review\">&quot;Overview of the complications of acute myeloid leukemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3009555264\"><span class=\"h3\">Acute promyelocytic leukemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acute promyelocytic leukemia (APL) with t(15;17) (formerly known as FAB M3 AML) is a distinct category of AML that constitutes a medical emergency. APL has unique clinical manifestations and complications and requires urgent and specific treatment that differs from other types of AML. APL is more likely when AML is associated with <span class=\"nowrap\">bleeding/bruising,</span> when leukemic blasts have coarse or dense cytoplasmic granules, and when there are few circulating leukemic cells or low WBC count. </p><p>APL responds equally well across the age spectrum to <a href=\"topic.htm?path=all-trans-retinoic-acid-systemic-tretinoin-drug-information\" class=\"drug drug_general\">all-trans retinoic acid</a> (ATRA) plus <a href=\"topic.htm?path=arsenic-trioxide-drug-information\" class=\"drug drug_general\">arsenic trioxide</a>. Details of the clinical manifestations, diagnosis, management, and outcomes of treatment of APL are presented separately. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-acute-promyelocytic-leukemia-in-adults\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults&quot;</a> and <a href=\"topic.htm?path=initial-treatment-of-acute-promyelocytic-leukemia-in-adults\" class=\"medical medical_review\">&quot;Initial treatment of acute promyelocytic leukemia in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H629514296\"><span class=\"h2\">Timing of initial therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Evaluation of medical fitness and <span class=\"nowrap\">cytogenetic/molecular</span> testing are important for individualizing treatment of AML in older patients, and these assessments should begin immediately after establishing the diagnosis of AML.</p><p>Except in the presence of medical emergencies, for most older patients it is not harmful to delay treatment of AML - other than APL - by 48 hours or longer to perform these evaluations and manage comorbid conditions to improve baseline physical function [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/13\" class=\"abstract_t\">13</a>]. (See <a href=\"#H2191324414\" class=\"local\">'Emergency management'</a> above.)</p><p>Rare patients have an indolent form of AML that does not require immediate treatment. Especially in patients with a <span class=\"nowrap\">&quot;hypoplastic/hypocellular&quot;</span> variant of AML, symptoms and complications are primarily associated with pancytopenia. For such patients, close observation <span class=\"nowrap\">and/or</span> supportive measures (eg, transfusion support, antibiotics) may more effectively enhance survival and quality of life than more intensive chemotherapy. (See <a href=\"topic.htm?path=induction-therapy-for-acute-myeloid-leukemia-in-younger-adults#H14\" class=\"medical medical_review\">&quot;Induction therapy for acute myeloid leukemia in younger adults&quot;, section on 'Supportive care'</a>.)</p><p class=\"headingAnchor\" id=\"H1951896920\"><span class=\"h2\">Benefits of treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Compared with supportive care alone, treatment of AML in older adults is associated with improved short-term and long-term outcomes [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/1,2,14-16\" class=\"abstract_t\">1,2,14-16</a>]. Benefits of treatment are seen whether the goal of treatment is cure or simply to extend survival, relieve symptoms, or improve quality of life.</p><p>Age is not a barrier to beneficial effects of AML treatment. Some population-based studies suggest that benefits of intensive therapy outweigh risks only in patients up to age 80 [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/1,2\" class=\"abstract_t\">1,2</a>]. However, retrospective studies have reported that selected patients in their 80s and 90s had high rates of response and improved survival when treated with intensive therapy [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/16,17\" class=\"abstract_t\">16,17</a>].</p><p>Some clinicians and patients fear the treatment will cause more harm than good. However, the major causes of death from AML in older patients are infection and hemorrhage related to disease-associated cytopenias [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/18\" class=\"abstract_t\">18</a>]. Treatment of the underlying AML is the most effective and efficient way to control those complications.</p><p>Studies that compare clinical outcomes of treatment versus supportive care in older patients with AML are discussed below. (See <a href=\"#H513801755\" class=\"local\">'Treatment outcomes'</a> below.)</p><p class=\"headingAnchor\" id=\"H1564444133\"><span class=\"h2\">Selection of initial therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Selection of initial therapy of AML is influenced by medical fitness, prognostic features of the AML cells, and goals of care.</p><p>Assessment of medical fitness and goals of care are discussed above. (See <a href=\"#H2593273779\" class=\"local\">'Determination of medical fitness'</a> above and <a href=\"#H1487970949\" class=\"local\">'Goals of care'</a> above.)</p><p>Cytogenetic and molecular prognostic features of AML cells are based on the European LeukemiaNet risk stratification scheme (<a href=\"image.htm?imageKey=HEME%2F111588\" class=\"graphic graphic_table graphicRef111588 \">table 3</a>) and are discussed separately. (See <a href=\"topic.htm?path=prognosis-of-acute-myeloid-leukemia#H25245420\" class=\"medical medical_review\">&quot;Prognosis of acute myeloid leukemia&quot;, section on 'European LeukemiaNet classification'</a>.)</p><p class=\"headingAnchor\" id=\"H3116630272\"><span class=\"h3\">Medically fit patients with favorable/intermediate prognosis AML</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For medically fit patients &ge;60 years old with favorable or intermediate prognostic features of AML, we suggest intensive remission induction therapy with curative intent, rather than alternative remission induction regimens, lower intensity treatments, or supportive care alone.</p><p>For intensive remission induction therapy in this setting, <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> by continuous infusion daily for seven days together with <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a> for three days (so-called &quot;7+3&quot; therapy) offers the most favorable balance of efficacy and toxicity; in certain circumstances we add a third agent to 7+3 therapy. (See <a href=\"#H3395673025\" class=\"local\">'Intensive remission induction (7+3 therapy)'</a> below.)</p><p>We do not withhold therapy based solely on the patient's age, but age does influence some therapeutic decisions (eg, <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a> dose), as described below. (See <a href=\"#H3395673025\" class=\"local\">'Intensive remission induction (7+3 therapy)'</a> below.)</p><p>Intensive treatment can achieve complete remission (CR) in about three-quarters of medically fit older patients with <span class=\"nowrap\">favorable/intermediate</span> prognostic features; median overall survival (OS) is approximately eight months, and five-year OS is 9 to 12 percent [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/6,19-22\" class=\"abstract_t\">6,19-22</a>].</p><p class=\"headingAnchor\" id=\"H2867001021\"><span class=\"h3\">Medically fit patients with adverse features of AML</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For medically fit older patients with adverse <span class=\"nowrap\">cytogenetic/molecular</span> features, outside of a clinical trial, we suggest treatment with CPX-351 or a hypomethylating agent (eg, <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a>, <a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a>) rather than 7+3 therapy, alternative remission induction regimens, other lower intensity treatments, or supportive care alone; CPX-351 is a liposomal formulation of <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> and <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a> in a fixed 5:1 molar ratio. (See <a href=\"#H3825144930\" class=\"local\">'CPX-351 (liposomal cytarabine/daunorubicin)'</a> below and <a href=\"#H1940102133\" class=\"local\">'Selection of lower intensity treatments'</a> below.) </p><p>For patients with adverse prognostic features, we judge that <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a> and <a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a> offer a more favorable balance of benefits and toxicities than 7+3 therapy. Decitabine and azacitidine achieve remissions in up to two-thirds of older patients with AML and can prolong survival when compared with supportive care alone [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/23-27\" class=\"abstract_t\">23-27</a>], and decitabine appears to be effective in patients with AML with mutations in <em>TP53</em> <span class=\"nowrap\">and/or</span> poor cytogenetic features [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/28\" class=\"abstract_t\">28</a>]. In older patients with therapy-related AML or AML with myelodysplasia-related changes, compared with 7+3 therapy, CPX-351 may offer superior outcomes with similar toxicity [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/29\" class=\"abstract_t\">29</a>].</p><p>In contrast, we judge that the toxicity of intensive remission induction therapy with 7+3 in older patients with adverse prognosis AML outweighs the low rates of response and survival. As an example, one study of intensive remission induction in adverse-risk AML reported &lt;45 percent CR rate, five-month median OS, and 28 percent one-year OS; 36 percent died within eight weeks [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/30\" class=\"abstract_t\">30</a>].</p><p>Because allogeneic HCT may be a consideration for post-remission therapy in medically fit older patients with adverse <span class=\"nowrap\">cytogenetic/molecular</span> features, we suggest HLA typing at diagnosis and referral for transplant consultation early in the course of care. (See <a href=\"#H3827308373\" class=\"local\">'Hematopoietic cell transplantation (HCT)'</a> below.)</p><p>Use of <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a> for treatment of AML and studies of hypomethylating agents versus intensive remission induction therapy or supportive care in older patients are discussed below. (See <a href=\"#H766270955\" class=\"local\">'Decitabine'</a> below and <a href=\"#H513801755\" class=\"local\">'Treatment outcomes'</a> below.)</p><p class=\"headingAnchor\" id=\"H723416755\"><span class=\"h3\">Intermediate medical fitness</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The category of intermediate medical fitness in older adults includes a broad range of physical function. Some patients have only modest, recent, or transient impairment of functional status, while others have substantial comorbid illnesses, cognitive impairment, or other conditions that may affect their ability to tolerate treatment. The disease burden of AML itself can contribute to lack of fitness, and achievement of remission may enhance a patient's ability to tolerate and benefit from additional, more intensive treatment.</p><p>Comprehensive geriatric consultation may aid in assessing the individual's ability to undergo and tolerate various therapies [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/11,12\" class=\"abstract_t\">11,12</a>]. (See <a href=\"#H2593273779\" class=\"local\">'Determination of medical fitness'</a> above.)</p><p>Selection of therapy in this setting is strongly influenced by the individual's goals of care, medical fitness, and prognostic features of AML cells:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with favorable or intermediate prognostic features of AML who are judged able to tolerate intensive remission induction, we treat with curative intent using 7+3 therapy; CPX-351 is an acceptable alternative where it is available. (See <a href=\"#H3395673025\" class=\"local\">'Intensive remission induction (7+3 therapy)'</a> below.)</p><p/><p class=\"bulletIndent1\">Alternative remission induction regimens (eg, <a href=\"topic.htm?path=gemtuzumab-ozogamicin-drug-information\" class=\"drug drug_general\">gemtuzumab ozogamicin</a>, <a href=\"topic.htm?path=cladribine-drug-information\" class=\"drug drug_general\">cladribine</a>) are also acceptable options in this setting. (See <a href=\"#H3298933996\" class=\"local\">'Alternative remission induction approaches'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with favorable or intermediate prognostic features of AML who are judged less likely to tolerate intensive remission induction therapy, or who place greater value on lessening toxicity than achieving cure, we treat with <a href=\"topic.htm?path=gemtuzumab-ozogamicin-drug-information\" class=\"drug drug_general\">gemtuzumab ozogamicin</a>, <a href=\"topic.htm?path=clofarabine-drug-information\" class=\"drug drug_general\">clofarabine</a>, or with lower intensity agents (eg, <a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a>, <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a>, or low dose <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a>). (See <a href=\"#H3298933996\" class=\"local\">'Alternative remission induction approaches'</a> below and <a href=\"#H2001081868\" class=\"local\">'Lower intensity treatments'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with favorable or intermediate prognostic features of AML whose functional limitations or personal goals emphasize palliation <span class=\"nowrap\">and/or</span> extension of survival, we treat with lower intensity treatments (eg, <a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a>, <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a>, or low dose <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a>) or supportive care. (See <a href=\"#H2001081868\" class=\"local\">'Lower intensity treatments'</a> below and <a href=\"#H2623334727\" class=\"local\">'Supportive care'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with adverse prognostic features of AML, we treat in the context of a clinical trial, with <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a> or <a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a>, or with supportive care alone. (See <a href=\"#H2001081868\" class=\"local\">'Lower intensity treatments'</a> below and <a href=\"#H2623334727\" class=\"local\">'Supportive care'</a> below.)</p><p/><p>Studies of various treatment approaches in older patients with AML that support these suggestions are described below. (See <a href=\"#H513801755\" class=\"local\">'Treatment outcomes'</a> below.)</p><p class=\"headingAnchor\" id=\"H369343491\"><span class=\"h3\">Medically frail patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of AML in medically frail patients is focused primarily on relief of symptoms, prolongation of life, and improving the quality of life. There is little likelihood of achieving long-term survival in this setting.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For medically frail patients with adverse prognostic features (especially <em>TP53</em> mutations) who choose treatment, we generally use <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a> or <a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a>, as discussed below. (See <a href=\"#H1940102133\" class=\"local\">'Selection of lower intensity treatments'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For other medically frail patients, we offer treatment with <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a>, <a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a>, low dose <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a>, or supportive care. (See <a href=\"#H2001081868\" class=\"local\">'Lower intensity treatments'</a> below.)</p><p/><p>Emphasis should be placed on controlling comorbid illnesses and lessening treatment toxicity. Discussion of goals, resources for personal assistance and transportation, a desire to avoid hospitalization, and other personal choices will influence decision-making in this setting.</p><p>Studies of outcomes in older patients with AML are described below. (See <a href=\"#H513801755\" class=\"local\">'Treatment outcomes'</a> below.)</p><p class=\"headingAnchor\" id=\"H2721395459\"><span class=\"h1\">INITIAL TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Selection of initial therapy of AML in older patients is discussed above. (See <a href=\"#H1487970949\" class=\"local\">'Goals of care'</a> above and <a href=\"#H1564444133\" class=\"local\">'Selection of initial therapy'</a> above.)</p><p class=\"headingAnchor\" id=\"H3395673025\"><span class=\"h2\">Intensive remission induction (7+3 therapy)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For medically fit older patients with favorable or intermediate prognostic features, and for select patients of intermediate fitness, we treat with intensive remission induction therapy with curative intent. (See <a href=\"#H3116630272\" class=\"local\">'Medically fit patients with favorable/intermediate prognosis AML'</a> above and <a href=\"#H723416755\" class=\"local\">'Intermediate medical fitness'</a> above.)</p><p>There is no general consensus regarding the optimal intensive remission induction therapy for older adults with AML. Our preferred regimen is a continuous infusion of <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> (100 or 200 <span class=\"nowrap\">mg/m<sup>2</sup></span> daily for seven days) together with <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a> (by short infusion or bolus for the first three days) or a similar anthracycline; such regimens are commonly referred to as &quot;7+3&quot; therapy. Additional details of 7+3 therapy, daunorubicin dose selection, and consideration of a third agent are provided below and separately. (See <a href=\"topic.htm?path=induction-therapy-for-acute-myeloid-leukemia-in-younger-adults\" class=\"medical medical_review\">&quot;Induction therapy for acute myeloid leukemia in younger adults&quot;</a>.)</p><p>An acceptable alternative to 7+3 therapy is treatment with CPX-351 (a liposomal formulation of <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> and <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a> in a fixed 5:1 molar ratio), as described below. (See <a href=\"#H3825144930\" class=\"local\">'CPX-351 (liposomal cytarabine/daunorubicin)'</a> below.)</p><p>Decisions regarding details of 7+3 therapy include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">Daunorubicin</a><strong> dosing:</strong></p><p/><p class=\"bulletIndent1\">We select the <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a> dose based on the patient's age:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients &le;65 years old, we generally treat with <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a> 90 <span class=\"nowrap\">mg/m<sup>2</sup></span> daily for three days</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients &gt;65 years old, we treat with <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a> 60 <span class=\"nowrap\">mg/m<sup>2</span> </sup>daily<sup> </sup>for three days</p><p/><p class=\"bulletIndent1\">In patients &le;65 years old, but not in patients &gt;65 years, <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a> 90 <span class=\"nowrap\">mg/m&sup2;</span> achieved better clinical outcomes without an increase in toxicity when compared with daunorubicin 45 <span class=\"nowrap\">mg/m&sup2;</span> [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/19\" class=\"abstract_t\">19</a>]. For patients 60 to 65 years old in this phase III trial, daunorubicin 90 <span class=\"nowrap\">mg/m&sup2;</span> achieved higher rates of complete remission (CR), two-year overall survival (OS), and two-year event-free survival (EFS). Daunorubicin 60 versus 90 <span class=\"nowrap\">mg/m&sup2;</span> have not been directly compared in prospective trials.</p><p/><p class=\"bulletIndent1\">In older patients with normal left ventricular function, age alone is not a reason to reduce <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a> dosing below these suggested levels [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/31\" class=\"abstract_t\">31</a>]. Older patients with significant heart disease (eg, congestive heart failure, myocardial infarction) may be categorized as being of intermediate medical fitness and ineligible for anthracycline-containing intensive remission induction therapy; cardiology consultation may be helpful in assessing the degree of cardiac compromise. (See <a href=\"#H723416755\" class=\"local\">'Intermediate medical fitness'</a> above.)</p><p/><p class=\"bulletIndent1\">Other anthracyclines (eg, <a href=\"topic.htm?path=idarubicin-drug-information\" class=\"drug drug_general\">idarubicin</a> or <a href=\"topic.htm?path=mitoxantrone-drug-information\" class=\"drug drug_general\">mitoxantrone</a>) are acceptable alternatives to <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a> and share similar clinical outcomes [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/32,33\" class=\"abstract_t\">32,33</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">Cytarabine</a><strong> dosing: </strong>No cytarabine regimen has proven more effective with less toxicity than a seven-day continuous infusion of cytarabine (100 or 200 <span class=\"nowrap\">mg/m&sup2;</span> daily) in older patients.</p><p/><p class=\"bulletIndent1\">In one trial, clinical outcomes and toxicity for <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> 100 versus 200 <span class=\"nowrap\">mg/m&sup2;</span> were comparable for patients &ge;60 years old [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/34\" class=\"abstract_t\">34</a>]. Cytarabine 200 <span class=\"nowrap\">mg/m&sup2;</span> daily was as effective as 400 <span class=\"nowrap\">mg/m<sup>2</sup></span> daily in another randomized trial [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/35\" class=\"abstract_t\">35</a>].</p><p/><p class=\"bulletIndent1\">High dose <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> (3 <span class=\"nowrap\">g/m<sup>2</sup></span> twice daily on days 1, 3, and 5) causes unacceptable neurologic toxicity in adults &gt;60 years old and should not be used in this setting [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/21\" class=\"abstract_t\">21</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Third agents:</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=gemtuzumab-ozogamicin-drug-information\" class=\"drug drug_general\">Gemtuzumab ozogamicin</a> &ndash; For older patients whose AML cells express CD33, we add gemtuzumab ozogamicin as a third agent to 7+3 therapy, where it is available. When added to 7+3 therapy, gemtuzumab ozogamicin is administered as 3 <span class=\"nowrap\">mg/m<sup>2</span> </sup>(up to one 4.5 mg vial) on days 1, 4, and 7. Further details about gemtuzumab ozogamicin are provided separately and below. (See <a href=\"topic.htm?path=induction-therapy-for-acute-myeloid-leukemia-in-younger-adults#H606166449\" class=\"medical medical_review\">&quot;Induction therapy for acute myeloid leukemia in younger adults&quot;, section on 'Gemtuzumab ozogamicin'</a> and <a href=\"#H65465221\" class=\"local\">'Gemtuzumab ozogamicin'</a> below.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Other agents</strong> &ndash; We add <a href=\"topic.htm?path=midostaurin-drug-information\" class=\"drug drug_general\">midostaurin</a> to 7+3 therapy for older patients with <em>FLT3</em> mutation. Although midostaurin has not been specifically examined as a third agent in patients &ge;60 years old, we judge that its benefits outweigh the toxicity in this setting. Use of single agent midostaurin in older patients for relapsed AML and midostaurin as a third agent in younger patients with AML are discussed below and separately. (See <a href=\"#H1516878732\" class=\"local\">'Relapsed or resistant AML'</a> below and <a href=\"topic.htm?path=induction-therapy-for-acute-myeloid-leukemia-in-younger-adults#H2358835507\" class=\"medical medical_review\">&quot;Induction therapy for acute myeloid leukemia in younger adults&quot;, section on 'Midostaurin in AML with FLT3 mutation'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Myeloid growth factors:</strong></p><p/><p class=\"bulletIndent1\">We suggest <strong>not</strong> routinely using myeloid growth factors (eg, granulocyte colony-stimulating factor [G-CSF], granulocyte-monocyte colony-stimulating factor [GM-CSF]) during remission induction therapy for older patients with AML. A meta-analysis that included more than 5000 patients from 19 clinical trials concluded that addition of myeloid growth factors to chemotherapy for AML adds toxicity and cost but does not provide identifiable benefits [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/36\" class=\"abstract_t\">36</a>]. Similar conclusions are drawn from prospective [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/37-39\" class=\"abstract_t\">37-39</a>] and retrospective studies [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/32,37-42\" class=\"abstract_t\">32,37-42</a>].</p><p/><p>Management of older patients who achieve remission is discussed below. (See <a href=\"#H544958330\" class=\"local\">'Post-remission management'</a> below.)</p><p>Studies that compared intensive remission induction therapy versus hypomethylating agents or supportive care in older adults are described below. (See <a href=\"#H513801755\" class=\"local\">'Treatment outcomes'</a> below.)</p><p class=\"headingAnchor\" id=\"H3825144930\"><span class=\"h2\">CPX-351 (liposomal cytarabine/daunorubicin)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CPX-351 is a liposomal formulation of <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> and <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a> in a fixed 5:1 molar ratio.</p><p>CPX-351 is approved by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes. FDA approval of CPX-351 carries a boxed warning advising against interchanging CPX-351 with other daunorubicin-containing <span class=\"nowrap\">and/or</span> cytarabine-containing products.</p><p>FDA approval of CPX-351 was based on a multicenter phase 3 trial of &gt;300 patients 60 to 75 years old with high risk AML [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/29\" class=\"abstract_t\">29</a>]. Compared to 7+3 therapy, CPX-351 achieved superior rates of CR (37 versus 26 percent, respectively), 12-month OS (42 versus 28 percent), and 24-month OS (31 versus 12 percent). Some of the longer surviving patients had undergone allogeneic transplantation. The rates and types of serious adverse events were similar in the two arms of the study.</p><p class=\"headingAnchor\" id=\"H3298933996\"><span class=\"h2\">Alternative remission induction approaches</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no consensus regarding a preferred alternative to 7+3 therapy for remission induction, nor how to select patients for such treatments.</p><p>Our preferred approach, outside of the context of a clinical trial, is <a href=\"topic.htm?path=gemtuzumab-ozogamicin-drug-information\" class=\"drug drug_general\">gemtuzumab ozogamicin</a> (GO) as a single-agent or in combination with <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a>, if the leukemic blasts express CD33 (the target of GO) and GO is available. (See <a href=\"#H65465221\" class=\"local\">'Gemtuzumab ozogamicin'</a> below.)</p><p>Other acceptable options include <a href=\"topic.htm?path=clofarabine-drug-information\" class=\"drug drug_general\">clofarabine</a> (alone or in combination with <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a>), or other non-anthracycline-containing regimens (eg, FLAG or CLAG) described below. (See <a href=\"#H1138846737\" class=\"local\">'Clofarabine and other regimens'</a> below.)</p><p>Although some alternative remission induction regimens have a more favorable side effect profile than 7+3 therapy, none is associated with more favorable clinical outcomes, as described below.</p><p class=\"headingAnchor\" id=\"H65465221\"><span class=\"h3\">Gemtuzumab ozogamicin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Single agent <a href=\"topic.htm?path=gemtuzumab-ozogamicin-drug-information\" class=\"drug drug_general\">gemtuzumab ozogamicin</a> (GO) is an acceptable remission induction therapy for select older patients whom we judge are unable to tolerate intensive 7+3 therapy [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/43\" class=\"abstract_t\">43</a>]. GO is not available in all medical settings.</p><p>We restrict use of single agent GO to patients of intermediate medical fitness with favorable or intermediate prognostic features and leukemic blast cells that express CD33, whom we judge are not able to tolerate 7+3 therapy. When used as a single agent for remission induction therapy, we treat with <a href=\"topic.htm?path=gemtuzumab-ozogamicin-drug-information\" class=\"drug drug_general\">gemtuzumab ozogamicin</a> 6 <span class=\"nowrap\">mg/m<sup>2</span> </sup>on day 1, and 3 <span class=\"nowrap\">mg/m<sup>2</span> </sup>on day 8, and continue treatment with GO for up to eight monthly cycles [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/44,45\" class=\"abstract_t\">44,45</a>].</p><p>The GO label includes a boxed warning about the risk of hepatotoxicity, including severe or fatal hepatic sinusoidal obstruction syndrome (also known as veno-occlusive disease) [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/45\" class=\"abstract_t\">45</a>]. GO is approved by the US Food and Drug Administration (FDA) as a single agent for newly diagnosed AML; it is also FDA-approved in combination with 7+3 therapy and for treatment of relapsed or refractory CD33+ AML in adults and in children &ge;2 years old [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/45\" class=\"abstract_t\">45</a>]. Details of its use in these settings are discussed separately. (See <a href=\"topic.htm?path=induction-therapy-for-acute-myeloid-leukemia-in-younger-adults#H606166449\" class=\"medical medical_review\">&quot;Induction therapy for acute myeloid leukemia in younger adults&quot;, section on 'Gemtuzumab ozogamicin'</a> and <a href=\"#H3395673025\" class=\"local\">'Intensive remission induction (7+3 therapy)'</a> above and <a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-acute-myeloid-leukemia#H8\" class=\"medical medical_review\">&quot;Treatment of relapsed or refractory acute myeloid leukemia&quot;, section on 'Remission re-induction'</a>.)</p><p>Induction therapy with single agent GO achieved one-year survival in about one-quarter of older adults with AML [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/45\" class=\"abstract_t\">45</a>], as described below. (See <a href=\"#H513801755\" class=\"local\">'Treatment outcomes'</a> below.)</p><p class=\"headingAnchor\" id=\"H1138846737\"><span class=\"h3\">Clofarabine and other regimens</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=clofarabine-drug-information\" class=\"drug drug_general\">Clofarabine</a> &ndash; We consider clofarabine an acceptable option for patients of intermediate medical fitness with favorable or intermediate prognosis who seek remission induction therapy, but whom we judge are unable to tolerate intensive remission induction therapy. Clofarabine is our preferred off-label agent for such patients whose leukemic blast cells do not express CD33 and where GO is not available.</p><p/><p class=\"bulletIndent1\">Single agent <a href=\"topic.htm?path=clofarabine-drug-information\" class=\"drug drug_general\">clofarabine</a> achieves responses in up to one-half of older patients with AML, including those considered unsuitable for anthracycline-based induction therapy [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/46\" class=\"abstract_t\">46</a>] and those with unfavorable risk factors [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/47\" class=\"abstract_t\">47</a>]. As an example, in a trial of 406 older adults with <span class=\"nowrap\">AML/high-risk</span> myelodysplastic syndrome who were not candidates for intensive induction therapy, patients randomly assigned to single agent clofarabine achieved 22 percent remission rate, 38 percent overall response, and 13 percent two-year OS [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/48\" class=\"abstract_t\">48</a>]. Compared with patients randomly assigned to low dose <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a>, there was no survival advantage, but clofarabine caused greater myelosuppression and gastrointestinal and hepatic toxicity.</p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=clofarabine-drug-information\" class=\"drug drug_general\">Clofarabine</a> has been studied in combination with other agents for AML induction. As an example, a prospective study reported similar clinical outcomes in patients who were randomly assigned to clofarabine plus <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a> versus <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> plus daunorubicin (69 percent response rate and 14 percent five-year OS) [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/49\" class=\"abstract_t\">49</a>]. Patients treated with clofarabine plus daunorubicin had slower recovery of platelet and neutrophil counts.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Other agents</strong> &ndash; Other agents and regimens have been studied in older patients with AML. While some regimens have a more favorable side effect profile than 7+3 therapy, none is associated with higher rates of CR, longer remission, <span class=\"nowrap\">and/or</span> improved OS [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/20,23,37,40,47,50-73\" class=\"abstract_t\">20,23,37,40,47,50-73</a>]. We generally favor GO, <a href=\"topic.htm?path=clofarabine-drug-information\" class=\"drug drug_general\">clofarabine</a>, or lower intensity treatments rather than these regimens. (See <a href=\"#H2001081868\" class=\"local\">'Lower intensity treatments'</a> below.)</p><p/><p class=\"bulletIndent1\">Examples of regimens that have been studied in AML include:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>FLAG (<a href=\"topic.htm?path=fludarabine-drug-information\" class=\"drug drug_general\">fludarabine</a>, <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a>, G-CSF) [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/74\" class=\"abstract_t\">74</a>]</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>CLAG (<a href=\"topic.htm?path=cladribine-drug-information\" class=\"drug drug_general\">cladribine</a>, <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a>, G-CSF) [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/75\" class=\"abstract_t\">75</a>]</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=vorinostat-drug-information\" class=\"drug drug_general\">Vorinostat</a> (histone deacetylase inhibitor) plus <a href=\"topic.htm?path=idarubicin-drug-information\" class=\"drug drug_general\">idarubicin</a> and <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/76\" class=\"abstract_t\">76</a>]</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=bortezomib-drug-information\" class=\"drug drug_general\">Bortezomib</a>, <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a>, and <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/77\" class=\"abstract_t\">77</a>]</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=lenalidomide-drug-information\" class=\"drug drug_general\">Lenalidomide</a> [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/78\" class=\"abstract_t\">78</a>]</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Modulators of drug efflux (eg, <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>, valspodar) [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/79,80\" class=\"abstract_t\">79,80</a>]</p><p/><p class=\"headingAnchor\" id=\"H2001081868\"><span class=\"h2\">Lower intensity treatments</span></p><p class=\"headingAnchor\" id=\"H1940102133\"><span class=\"h3\">Selection of lower intensity treatments</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Our approach to the selection of lower intensity treatments follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with adverse prognostic features (especially <em>TP53</em> mutations) with any level of medical fitness who seek treatment outside of the context of a clinical trial, we generally use a 10-day schedule of <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a> due to its effectiveness in this setting, as described below. (See <a href=\"#H766270955\" class=\"local\">'Decitabine'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For other older adults with AML who seek treatment for AML but are unable to undergo more intensive treatments, we offer either <a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a> or <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a>.</p><p/><p class=\"bulletIndent1\">Some experts consider low dose <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> an acceptable alternative in this setting, but it has little benefit and should not be used in patients with adverse prognostic features of AML, as described below. (See <a href=\"#H1002009560\" class=\"local\">'Low dose cytarabine'</a> below.)</p><p/><p>Some patients <span class=\"nowrap\">and/or</span> clinicians prefer <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a> because it is given intravenously; others prefer <a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a> because its subcutaneous administration requires less time in an infusion center. Low dose <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> may be an option for patients whose comorbid conditions (eg, renal insufficiency) preclude other treatments or who seek treatment at home rather than in daily clinic visits.</p><p>No prospective trials have directly compared <a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a>, <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a>, and low dose <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> in older patients with AML. Azacitidine and decitabine can induce remissions and potentially prolong survival in a subset of older patients with newly diagnosed AML, and both have demonstrated superior response rates when compared with supportive care alone [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/23-27,70,73,81-84\" class=\"abstract_t\">23-27,70,73,81-84</a>]. Low dose cytarabine appears less effective than azacitidine and decitabine but achieved superior rates of response and survival when compared with supportive care alone [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/85\" class=\"abstract_t\">85</a>]. Studies of these agents are described below. (See <a href=\"#H513801755\" class=\"local\">'Treatment outcomes'</a> below.)</p><p>Although these agents are relatively well tolerated, they do cause myelosuppression. Transfusion support is usually required, neutropenia may occur, and prophylactic antibiotics should be considered.</p><p>The European Medicines Agency (EMA) has approved <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a> for the treatment of AML, and it approved <a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a> for the treatment of AML that developed from myelodysplastic syndrome, if patients are not candidates for intensive chemotherapy. Neither agent has been approved by the FDA for treatment of AML.</p><p class=\"headingAnchor\" id=\"H3562734933\"><span class=\"h4\">Azacitidine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">Azacitidine</a> is usually administered in an outpatient setting over seven days (eg, 75 <span class=\"nowrap\">mg/m<sup>2</sup></span> per day subcutaneously every 28 days) [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/86\" class=\"abstract_t\">86</a>], but more convenient dosing regimens (eg, 100 <span class=\"nowrap\">mg/m<sup>2</sup></span> per day for five consecutive days every 28 days) are acceptable options [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/87\" class=\"abstract_t\">87</a>]. We generally evaluate response after two to four treatment cycles, but best responses may not occur until six cycles have been given. Most patients will have at least one hospitalization for neutropenic fever during this time. Growth factor support and dose adjustment may be necessary for some patients (eg, renal toxicity).</p><p><a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">Azacitidine</a> can achieve responses in more than one-half of older patients with AML and may prolong survival when compared with supportive care alone. Studies that compare azacitidine versus other treatments <span class=\"nowrap\">and/or</span> supportive care are described below. (See <a href=\"#H513801755\" class=\"local\">'Treatment outcomes'</a> below.)</p><p>Examples of trials examining <a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a> in AML include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An international open-label trial that included more than 300 adults &ge;65 years old treated with <a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a> reported 12-month median OS and 20 percent two-year OS [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/88\" class=\"abstract_t\">88</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In AZA-001, median OS was 25 months in older patients with AML who were treated with <a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a> [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/86\" class=\"abstract_t\">86</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In CALGB 9221, patients who received <a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a> achieved 60 percent overall response rate (including 7 percent CR) and improved physical function, symptoms, and psychologic state [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/84\" class=\"abstract_t\">84</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">Azacitidine</a> treatment in 35 patients with AML achieved CR or CR with incomplete (CRi) blood count recovery in 31 percent and median response duration was 13 months [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/73\" class=\"abstract_t\">73</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A single arm, dose-finding study reported that <a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a> plus <a href=\"topic.htm?path=venetoclax-drug-information\" class=\"drug drug_general\">venetoclax</a> (an inhibitor of the anti-apoptotic protein, BCL2) achieved 59 percent rate of CR plus CRi, and was well-tolerated [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/89\" class=\"abstract_t\">89</a>].</p><p/><p class=\"headingAnchor\" id=\"H766270955\"><span class=\"h4\">Decitabine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">Decitabine</a> can be administered in an outpatient setting (eg, 20 <span class=\"nowrap\">mg/m<sup>2</sup></span> intravenously [IV] over one hour daily for 10 or 5 consecutive days, every four weeks) [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/23,24,28,90,91\" class=\"abstract_t\">23,24,28,90,91</a>]. Decitabine can also be administered in the inpatient setting (eg, 15 <span class=\"nowrap\">mg/m<sup>2</sup></span> IV over four hours every eight hours for three consecutive days, every six weeks) [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/26\" class=\"abstract_t\">26</a>]. Response to decitabine typically requires at least two cycles of treatment, and treatment should be continued for as long as a benefit persists with tolerable side effects. Growth factor support and dose adjustment may be necessary for some patients (eg, renal toxicity).</p><p><a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">Decitabine</a> appears to be effective in patients with AML with mutations in <em>TP53</em> <span class=\"nowrap\">and/or</span> unfavorable cytogenetic features [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/28\" class=\"abstract_t\">28</a>]. Compared with treatment for five consecutive days, treatment for 10 consecutive days may achieve higher response rates [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/25,90,91\" class=\"abstract_t\">25,90,91</a>].</p><p><a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">Decitabine</a> achieves CR or CRp (CR without platelet recovery) in up to half of patients with AML, with a median OS of five to eight months [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/23-26,28,70,90-92\" class=\"abstract_t\">23-26,28,70,90-92</a>].</p><p>Examples of trials that evaluated <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a> in older patients with AML include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A multicenter study reported that <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a> (20 <span class=\"nowrap\">mg/m<sup>2</sup></span> for 10 consecutive days) achieved clearance of bone marrow blasts in nearly half of 54 patients &ge;60 years old [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/28\" class=\"abstract_t\">28</a>]. Response rates were higher in patients with unfavorable-risk cytogenetics (67 percent of 43 patients) and <em>TP53</em> mutation (100 percent of 21 patients), compared with intermediate-risk or favorable-risk cytogenetics (34 percent) and wild-type <em>TP53</em> (41 percent). Maximum clinical response required at least two cycles of treatment.</p><p/><p class=\"bulletIndent1\">Other studies that used 10-day <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a> regimens reported CR rates of 30 to 47 percent [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/25,90,91\" class=\"abstract_t\">25,90,91</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a multicenter study, patients treated with <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a> (five-day treatment every four weeks) achieved 18 percent CR plus CRp and eight-month median OS, but had high rates of febrile neutropenia and pneumonia (24 and 20 percent, respectively) [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/24\" class=\"abstract_t\">24</a>]. Another multicenter study reported similar response rates and toxicity [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/23\" class=\"abstract_t\">23</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a multicenter study of 227 older adults (median age 72 years) who were ineligible for intensive induction chemotherapy, <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a> (135 <span class=\"nowrap\">mg/m<sup>2</sup></span> total dose infused over 72 hours every six weeks) achieved 13 percent CR, six-month median OS, and one-year and two-year OS rates were 28 and 13 percent, respectively [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/26\" class=\"abstract_t\">26</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A single arm, dose-finding study reported that <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a> plus <a href=\"topic.htm?path=venetoclax-drug-information\" class=\"drug drug_general\">venetoclax</a> (an inhibitor of the anti-apoptotic protein, BCL2) achieved 61 percent rate of CR plus Cri, and was well-tolerated [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/89\" class=\"abstract_t\">89</a>].</p><p/><p class=\"headingAnchor\" id=\"H1002009560\"><span class=\"h4\">Low dose cytarabine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Low dose <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> has limited therapeutic efficacy in AML, but some experts consider it an acceptable option for older patients with favorable- or intermediate-risk karyotype AML whose comorbid conditions (eg, renal insufficiency) preclude other treatment, or for those who seek to receive treatment at home rather than in daily clinic visits or hospitalization.</p><p>Low dose <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> can be administered subcutaneously 20 mg twice daily for 10 to 14 days every four weeks [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/85\" class=\"abstract_t\">85</a>] or 75 <span class=\"nowrap\">mg/m<sup>2</sup>/d</span> for seven days every four weeks [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/70\" class=\"abstract_t\">70</a>]. Low dose cytarabine appears to be ineffective in patients whose AML has adverse prognostic features [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/24,70,85\" class=\"abstract_t\">24,70,85</a>], and it should not be given in that setting.</p><p>Treatment of AML with low dose <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> can prolong survival and achieve remission in a subset of patients with AML. Examples of studies of low dose cytarabine in older patients with AML include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a multicenter phase III trial, 217 patients with AML or high-risk myelodysplastic syndrome were randomly assigned to receive low dose <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> (20 mg twice daily for 10 days) or <a href=\"topic.htm?path=hydroxyurea-hydroxycarbamide-drug-information\" class=\"drug drug_general\">hydroxyurea</a> [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/85\" class=\"abstract_t\">85</a>]. When compared with hydroxyurea, low dose cytarabine resulted in a higher remission rate (18 versus 1 percent, respectively) and improved OS (HR 0.60; 95% CI 0.44-0.81). Toxicity was generally mild, with the most common grade <span class=\"nowrap\">3/4</span> toxicities being cardiac (10 percent), <span class=\"nowrap\">nausea/vomiting</span> (6 percent), and diarrhea (4 percent).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A multicenter study randomly assigned 87 patients &gt;65 years old to low dose <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> (10 <span class=\"nowrap\">mg/m<sup>2</sup></span> every 12 hours for 21 days) versus intensive chemotherapy, and reported that low dose cytarabine achieved 32 percent CR and 22 percent partial response [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/93\" class=\"abstract_t\">93</a>]. There was no difference in OS or remission duration between the two arms of the study, but intensive therapy was associated with more CRs (52 percent) and more early deaths.</p><p/><p class=\"headingAnchor\" id=\"H2623334727\"><span class=\"h2\">Supportive care</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other measures of supportive care include transfusions with red blood cells and platelets as needed, and the use of antibiotics to treat infections. (See <a href=\"topic.htm?path=induction-therapy-for-acute-myeloid-leukemia-in-younger-adults#H14\" class=\"medical medical_review\">&quot;Induction therapy for acute myeloid leukemia in younger adults&quot;, section on 'Supportive care'</a>.)</p><p>Prospective and retrospective studies report that, compared with supportive care alone, various forms of treatment of AML are associated with improved survival, better relief of symptoms, and a similar amount of remaining days spent in the hospital, as described below. (See <a href=\"#H513801755\" class=\"local\">'Treatment outcomes'</a> below.)</p><p class=\"headingAnchor\" id=\"H219716188\"><span class=\"h1\">RESPONSE EVALUATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The goal of remission induction chemotherapy is complete remission and rapid restoration of normal bone marrow function. Unilateral bone marrow aspirate and biopsy is typically performed seven days after the final doses of induction chemotherapy and repeated after recovery of blood counts (eg, approximately four weeks after treatment began). Definitions and criteria for remission are presented separately. (See <a href=\"topic.htm?path=remission-criteria-in-acute-myeloid-leukemia-and-monitoring-for-residual-disease#H2\" class=\"medical medical_review\">&quot;Remission criteria in acute myeloid leukemia and monitoring for residual disease&quot;, section on 'Definition of complete remission (CR)'</a>.)</p><p>Management of patients with AML that failed to respond to initial therapy (ie, resistant AML) is discussed below. (See <a href=\"#H1516878732\" class=\"local\">'Relapsed or resistant AML'</a> below.)</p><p>For patients who undergo treatment with less intensive therapy (eg, hypomethylating agents), assessment generally focuses on achieving functional responses, such as reducing transfusion needs, avoiding hospitalization, and controlling other symptoms. If clinically indicated by changes in the peripheral blood counts, bone marrow examination may be performed after several cycles of therapy.</p><p>Following the completion of all therapy (intensive, lower intensity, or post-remission), patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. Details of post-consolidation surveillance are presented separately. (See <a href=\"topic.htm?path=post-remission-therapy-for-acute-myeloid-leukemia-in-younger-adults#H18\" class=\"medical medical_review\">&quot;Post-remission therapy for acute myeloid leukemia in younger adults&quot;, section on 'Post-consolidation management'</a>.)</p><p class=\"headingAnchor\" id=\"H544958330\"><span class=\"h1\">POST-REMISSION MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Virtually all patients who achieve remission with initial therapy of AML will relapse within months unless additional therapy is given. Post-remission therapy aims to destroy leukemic cells that survived induction chemotherapy but are undetectable by conventional studies. This approach offers the only meaningful opportunity for long-term survival in AML, but potential benefits must be weighed against high rates of treatment-related toxicity in older patients.</p><p>Our preferred approach is participation in a clinical trial evaluating immunotherapy or a targeted agent. Clinicians should discuss treatment options, including risks, benefits, and likely outcomes with candidates for post-remission therapy. A decision to proceed with post-remission therapy should be finalized soon after achieving complete remission (CR), as most patients will soon relapse, and treatment outcomes for relapsed AML are uniformly poor.</p><p>Any medically fit older patient who achieves CR is potentially a candidate for post-remission therapy, including those treated with 7+3 therapy (infusional <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> plus <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a>), alternative remission induction regimens, or lower intensity treatments (eg, <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a> or <a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a>).</p><p>Following the completion of post-remission therapy, patients are seen at periodic intervals to monitor for treatment complications and possible relapse. Details of post-remission and post-consolidation surveillance are presented separately. (See <a href=\"topic.htm?path=post-remission-therapy-for-acute-myeloid-leukemia-in-younger-adults#H18\" class=\"medical medical_review\">&quot;Post-remission therapy for acute myeloid leukemia in younger adults&quot;, section on 'Post-consolidation management'</a>.)</p><p class=\"headingAnchor\" id=\"H2828774744\"><span class=\"h2\">Selection of post-remission therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no consensus regarding optimal post-remission management for older patients with AML. Treatment options in this setting include consolidation chemotherapy versus allogeneic hematopoietic cell transplantation (HCT); maintenance therapy is acceptable for select older patients with AML in remission, as discussed below.</p><p>No prospective trials have directly compared observation versus consolidation chemotherapy, allogeneic HCT, or maintenance therapy in older patients with AML. Retrospective studies may be subject to bias due to selection of younger, more medically fit, <span class=\"nowrap\">and/or</span> prognostically favorable patients being referred for post-remission treatment. Post-remission management decisions are informed by the patient's fitness to undergo further therapy and prognostic features of the AML cells.</p><p>Our approach follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For medically fit older adults (and select robust patients of intermediate fitness) with favorable or intermediate prognosis AML in first CR, we suggest consolidation chemotherapy with intermediate dose <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> rather than allogeneic HCT, high dose cytarabine, other chemotherapy regimens, or observation alone. (See <a href=\"#H43344244\" class=\"local\">'Consolidation chemotherapy'</a> below.)</p><p/><p class=\"bulletIndent1\">Our preference for this approach places a higher value on lessening toxicity and a lower value on the potential benefit of a graft-versus-leukemia effect associated with allogeneic HCT.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For medically fit patients &le;75 years old with adverse-risk AML, we offer nonmyeloablative (NMA) or reduced intensity conditioning (RIC) allogeneic HCT (preferably in the context of a clinical trial), rather than myeloablative allogeneic HCT, consolidation chemotherapy, or observation alone. (See <a href=\"#H3827308373\" class=\"local\">'Hematopoietic cell transplantation (HCT)'</a> below.)</p><p/><p class=\"bulletIndent1\">In the setting of adverse prognostic factors, NMA and RIC allogeneic HCT offer the potential for graft-versus-leukemia effect without the unacceptable toxicity of myeloablative allogeneic HCT for older patients, whereas outcomes with consolidation chemotherapy in this setting are uniformly poor.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Medically frail patients, most patients of intermediate medical fitness, and medically fit patients other than those described above are not candidates for post-remission therapy. For these patients, we monitor as described separately. (See <a href=\"topic.htm?path=post-remission-therapy-for-acute-myeloid-leukemia-in-younger-adults#H18\" class=\"medical medical_review\">&quot;Post-remission therapy for acute myeloid leukemia in younger adults&quot;, section on 'Post-consolidation management'</a>.)</p><p/><p>A detailed description of post-remission therapy in younger adults is presented separately. (See <a href=\"topic.htm?path=post-remission-therapy-for-acute-myeloid-leukemia-in-younger-adults\" class=\"medical medical_review\">&quot;Post-remission therapy for acute myeloid leukemia in younger adults&quot;</a>.)</p><p>A retrospective study compared outcomes of patients 60 to 70 years old with AML in first CR who underwent RIC allogeneic HCT (94 patients) versus consolidation chemotherapy (96 patients) [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/94\" class=\"abstract_t\">94</a>]. Compared with consolidation chemotherapy, HCT was associated with a lower risk of relapse (32 versus 81 percent), better three-year disease-free survival (DFS; 32 versus 15 percent), and a trend toward increased three-year overall survival (OS; 37 versus 25 percent), but higher nonrelapse mortality (NRM; 36 versus 4 percent, respectively). The groups were well balanced for cytogenetic risk groups and inclusion of therapy-related leukemia, but patients undergoing HCT were younger (median age 63 versus 65 years).</p><p>Maintenance therapy is discussed below. (See <a href=\"#H2621482413\" class=\"local\">'Maintenance therapy'</a> below.)</p><p class=\"headingAnchor\" id=\"H43344244\"><span class=\"h3\">Consolidation chemotherapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no consensus regarding the optimal consolidation chemotherapy regimen or number of treatment cycles for older adults.</p><p>Our preferred approach in older adults is two to four cycles of intermediate dose <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> (eg, 1000 <span class=\"nowrap\">mg/m<sup>2</sup></span> daily for five days). An acceptable alternative is treatment with cytarabine (100 to 200 <span class=\"nowrap\">mg/m<sup>2</sup></span> per day for five days) plus <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a> (30 to 45 <span class=\"nowrap\">mg/m<sup>2</sup></span> for two days).</p><p>For patients who received <a href=\"topic.htm?path=gemtuzumab-ozogamicin-drug-information\" class=\"drug drug_general\">gemtuzumab ozogamicin</a> (GO) during remission induction therapy, we include GO (2 <span class=\"nowrap\">mg/m<sup>2</span> </sup>on day 1 concurrently with <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a>) in consolidation therapy. The clinical benefit of GO in post-remission therapy has not been fully evaluated. Maintenance therapy with single agent GO is an acceptable alternative, as described below. (See <a href=\"#H2621482413\" class=\"local\">'Maintenance therapy'</a> below.)</p><p>For patients with <em>FLT3</em> mutation who received <a href=\"topic.htm?path=midostaurin-drug-information\" class=\"drug drug_general\">midostaurin</a> during remission induction therapy, we continue midostaurin treatment through consolidation therapy. High dose <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a>, the standard consolidation chemotherapy for younger adults with favorable-risk AML, is associated with unacceptably high rates of severe toxicity and early death in older adults [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/21\" class=\"abstract_t\">21</a>].</p><p>The following studies have investigated consolidation chemotherapy in older adults:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A French study randomly assigned 164 patients &ge;65 years old to either six monthly courses of outpatient consolidation chemotherapy or a second course of intensive induction therapy [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/95\" class=\"abstract_t\">95</a>]. Two years after attaining CR, consolidation therapy was associated with superior rates of OS (56 versus 37 percent) and DFS (28 versus 17 percent), reduced transfusion needs, and shorter periods of rehospitalization.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A CALGB trial randomly assigned 163 patients &ge;60 years old to consolidation with <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> alone or cytarabine plus <a href=\"topic.htm?path=mitoxantrone-drug-information\" class=\"drug drug_general\">mitoxantrone</a>, and reported no difference in DFS (11 and 10 months, respectively), but greater toxicity in the cytarabine plus mitoxantrone arm [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/37\" class=\"abstract_t\">37</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another CALGB trial, DFS did not differ based on random assignment to various <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> consolidation regimens; overall four-year DFS was 14 percent [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/21\" class=\"abstract_t\">21</a>]. High dose cytarabine caused cerebellar ataxia in more than one-third of patients &gt;60 years old, and was irreversible in some.</p><p/><p class=\"headingAnchor\" id=\"H3827308373\"><span class=\"h3\">Hematopoietic cell transplantation (HCT)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Allogeneic HCT is appropriate for select older patients with AML as post-remission therapy. There is no proven role for autologous HCT as consolidation therapy in older patients with AML.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Allogeneic HCT</strong> &ndash; Retrospective and population-based studies suggest that allogeneic HCT is beneficial for select older patients with AML, but such retrospective studies are subject to bias regarding patient selection. No randomized trials in older adults have directly compared allogeneic HCT versus consolidation chemotherapy or observation in this setting.</p><p/><p class=\"bulletIndent1\">We offer RIC or NMA allogeneic HCT to medically fit (<a href=\"image.htm?imageKey=HEME%2F59272\" class=\"graphic graphic_table graphicRef59272 \">table 4</a>) patients &le;75 years old with adverse prognostic features. (See <a href=\"topic.htm?path=determining-eligibility-for-allogeneic-hematopoietic-cell-transplantation\" class=\"medical medical_review\">&quot;Determining eligibility for allogeneic hematopoietic cell transplantation&quot;</a>.)</p><p/><p class=\"bulletIndent1\">Allogeneic HCT in older patients generally uses either RIC or NMA conditioning, which offer a reasonable balance between graft-versus-leukemia effect and graft-versus-host disease without the unacceptable toxicity of myeloablative allogeneic HCT. Consultation with HCT physicians should be obtained by the time of achieving CR to enable clinical evaluation and initiate a search for potential sources of donor cells. Descriptions of RIC and NMA allogeneic HCT as post-remission therapy for AML are provided separately. (See <a href=\"topic.htm?path=post-remission-therapy-for-acute-myeloid-leukemia-in-younger-adults#H17\" class=\"medical medical_review\">&quot;Post-remission therapy for acute myeloid leukemia in younger adults&quot;, section on 'Nonmyeloablative/Reduced intensity HCT'</a>.)</p><p/><p class=\"bulletIndent1\">Examples of retrospective studies that have reported the use of RIC or NMA regimens in older adults with AML include:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A retrospective study of patients who underwent RIC or NMA allogeneic HCT reported two-year OS rates of 34 and 36 percent for patients with AML aged 60 to 64 versus &ge;65 years, respectively [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/96\" class=\"abstract_t\">96</a>]. Multivariate analysis revealed no significant impact of age on rates of OS, DFS, relapse, and NRM. OS was adversely affected by unfavorable prognostic features and greater HLA disparity.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A retrospective study in 94 adults 60 to 70 years old reported that RIC allogeneic HCT was associated with 32 percent three-year DFS, 37 percent three-year OS, and 36 percent NRM [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/94\" class=\"abstract_t\">94</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Retrospective analysis of SEER (Surveillance, Epidemiology, and End Results)-Medicare data reported 50 and 31 percent two-year OS among patients aged 65 to 69 and 70 to 74 years, respectively, who underwent allogeneic HCT [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/1\" class=\"abstract_t\">1</a>]. Among the entire cohort of more than 5000 patients with AML, the 46 who underwent allogeneic HCT had the longest OS, compared with those who received AML treatment alone (22 versus 6 months versus 3 months, respectively).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Autologous HCT</strong> &ndash; There is no demonstrated role for autologous HCT as consolidation therapy in older patients with AML. Although autologous HCT causes less short- and long-term toxicity than allogeneic HCT, it does not provide the benefit of a graft-versus-leukemia effect.</p><p/><p class=\"headingAnchor\" id=\"H2621482413\"><span class=\"h3\">Maintenance therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Maintenance therapy is designed to sustain a remission in AML, and is an acceptable option for select older patients, as described below. </p><p>We offer maintenance therapy as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=gemtuzumab-ozogamicin-drug-information\" class=\"drug drug_general\">Gemtuzumab ozogamicin</a><strong> (GO)</strong> &ndash; Maintenance therapy with gemtuzumab ozogamicin (GO) is an acceptable alternative to consolidation therapy with GO. (See <a href=\"#H43344244\" class=\"local\">'Consolidation chemotherapy'</a> above.)</p><p/><p class=\"bulletIndent1\">For maintenance therapy, single agent <a href=\"topic.htm?path=gemtuzumab-ozogamicin-drug-information\" class=\"drug drug_general\">gemtuzumab ozogamicin</a> is administered at 2 <span class=\"nowrap\">mg/m<sup>2</span> </sup>on day 1 every four weeks for up to eight cycles [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/44,45\" class=\"abstract_t\">44,45</a>]. Maintenance therapy with GO is restricted to patients whose AML cells express CD33 and where it is available.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=midostaurin-drug-information\" class=\"drug drug_general\">Midostaurin</a><strong> </strong>&ndash; Midostaurin is administered as maintenance therapy for patients with <em>FLT3</em> mutation who received it during remission induction therapy <span class=\"nowrap\">and/or</span> consolidation therapy.</p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=midostaurin-drug-information\" class=\"drug drug_general\">Midostaurin</a> is given as a single agent at a dose of 50 mg orally twice daily on days 8 through 21, for 12 28-day cycles (ie, for one year after completing consolidation therapy) to patients with <em>FLT3</em> mutant AML, where it is available.</p><p/><p>There is no proven benefit for other maintenance therapy (eg, low dose <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a>, low dose interferon alfa, <a href=\"topic.htm?path=enasidenib-drug-information\" class=\"drug drug_general\">enasidenib</a>) in older patients with AML who have attained complete remission on 7+3-like therapy [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/33,40\" class=\"abstract_t\">33,40</a>].</p><p class=\"headingAnchor\" id=\"H1516878732\"><span class=\"h1\">RELAPSED OR RESISTANT AML</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>AML that recurs after initial response (relapsed AML) or that fails to respond to initial induction therapy (resistant AML) in older patients generally has a grim prognosis. The preferred option for management of relapsed or resistant AML in older patients is participation in a clinical trial.</p><p>Outside of the context of a clinical trial, acceptable options include treatment with <a href=\"topic.htm?path=gemtuzumab-ozogamicin-drug-information\" class=\"drug drug_general\">gemtuzumab ozogamicin</a> (where available) [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/45\" class=\"abstract_t\">45</a>], <a href=\"topic.htm?path=midostaurin-drug-information\" class=\"drug drug_general\">midostaurin</a> (for AML with <em>FLT3</em> mutation) [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/97\" class=\"abstract_t\">97</a>], <a href=\"topic.htm?path=enasidenib-drug-information\" class=\"drug drug_general\">enasidenib</a> (for AML with <em>IDH2</em> mutation) [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/98\" class=\"abstract_t\">98</a>], alternative chemotherapy regimens, lower intensity treatments (eg, <a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a>, <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a>), or palliative management. (See <a href=\"#H2721395459\" class=\"local\">'Initial treatment'</a> above.)</p><p>Management of relapsed and refractory AML in younger patients is described separately. (See <a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-acute-myeloid-leukemia\" class=\"medical medical_review\">&quot;Treatment of relapsed or refractory acute myeloid leukemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H513801755\"><span class=\"h1\">TREATMENT OUTCOMES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Studies that describe outcomes of older patients with AML are described below.</p><p class=\"headingAnchor\" id=\"H361018781\"><span class=\"h2\">Treatment versus supportive care alone</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Compared with supportive care alone, treatment of AML in older adults is associated with improved short-term and long-term outcomes. Treatment of AML improves the quality of life, including fewer hospitalizations and less need for transfusions and antibiotics [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/2,14\" class=\"abstract_t\">2,14</a>]. Improved outcomes are reported in both prospective trials and population-based studies, even while recognizing that retrospective analyses may exhibit a bias that favors treatment for more medically fit <span class=\"nowrap\">and/or</span> younger patients (eg, 60 to 65 years old).</p><p>Examples of studies that compared various treatments versus best supportive care in older patients with AML include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Intensive therapy versus supportive care</strong> &ndash; A prospective trial that randomly assigned 60 patients &gt;65 years old to intensive therapy versus supportive care reported longer median overall survival (OS) in those receiving intensive remission induction therapy (21 versus 11 weeks, respectively); the two groups spent a similar percentage of their remaining days in the hospital (54 versus 50 percent) [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/14\" class=\"abstract_t\">14</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=gemtuzumab-ozogamicin-drug-information\" class=\"drug drug_general\">Gemtuzumab ozogamicin</a><strong> (GO) versus supportive care</strong> &ndash; A prospective study of 237 adults &ge;61 years old that randomly assigned patients to single agent GO versus best supportive care reported that GO achieved superior median OS (five versus four months, respectively; HR 0.69, 95% CI 0.53-0.90) and one-year OS (24 versus 10 percent); rates of serious adverse events were similar in both arms of the study [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/53\" class=\"abstract_t\">53</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Intensive therapy or </strong><a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a><strong> versus supportive care</strong> &ndash; A retrospective study of 227 patients &ge;60 years old treated with intensive chemotherapy (90 patients), azacitidine (26 patients), or best supportive care (97 patients) reported that, compared with supportive care only, both treatments yielded superior one-year and two-year OS [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/19\" class=\"abstract_t\">19</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Population-based studies</strong> &ndash; A Swedish registry study that included 2767 patients with AML (more than three-quarters of whom were &ge;60 years old) reported that early death rates were lower with intensive therapy than with palliation only [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/2\" class=\"abstract_t\">2</a>]. Outcomes were strongly dependent on age and performance status but, in all age cohorts, early death rates were lower with intensive therapy. OS of older patients was better in geographic regions where most patients were given intensive therapy.</p><p/><p class=\"bulletIndent1\">United States SEER (Surveillance, Epidemiology, and End Results)-Medicare data of 5480 patients &ge;65 years (median age 78 years) reported longer OS in patients who were treated compared with untreated patients (median 6 versus 2 months, respectively) [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/1\" class=\"abstract_t\">1</a>]. Treatment-associated improvements in OS were especially apparent in those aged 65 to 69 (10 versus 4 months, respectively), 70 to 74 (8 versus 3 months, respectively), and 75 to 79 years (6 versus 2 months).</p><p/><p class=\"headingAnchor\" id=\"H3153621328\"><span class=\"h2\">Intensive treatment versus hypomethylating agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>No prospective trials have directly compared intensive treatment versus hypomethylating agents (<a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a>, <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a>) as initial therapy of AML in older patients. Retrospective studies suggest that, compared with hypomethylating agents, intensive treatment achieved higher rates of response but comparable OS.</p><p>Examples of studies that evaluated these treatment approaches in older patients include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A retrospective analysis of 671 patients &ge;65 years old reported that, compared with DNA hypomethylating agents (<a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a> or <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a>), intensive therapy achieved higher rates of CR (42 versus 28 percent, respectively), but there was no difference in rates of early death, two-year relapse-free survival, or median OS [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/27\" class=\"abstract_t\">27</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Retrospective analysis of 227 AML patients &ge;60 years old treated with intensive chemotherapy (90 patients), <a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a> (26 patients), or best supportive care (97 patients) reported similar one-year OS and two-year OS after intensive therapy versus azacitidine; both treatments were superior to supportive care only [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/99\" class=\"abstract_t\">99</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A retrospective analysis of 167 consecutive AML patients &ge;60 years old reported that, compared with DNA hypomethylating agents, intensive therapy achieved higher rates of CR (43 versus 20 percent, respectively) and overall response (50 versus 28 percent), but multivariate analysis showed no independent impact of treatment on OS [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/100\" class=\"abstract_t\">100</a>].</p><p/><p class=\"headingAnchor\" id=\"H27\"><span class=\"h1\">CLINICAL TRIALS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial.</p><p>Only a minority of newly diagnosed older adults with AML are currently enrolled in clinical trials in the United States. Examples of this problem include the following observations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Adults &ge;65 years old represent more than 60 percent of the United States population of patients with cancer, but they accounted for only 27 percent of patients enrolled in leukemia clinical trials sponsored by the Southwest Oncology Group [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/101\" class=\"abstract_t\">101</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a Swiss study, in which only 45 percent of 170 newly diagnosed patients with AML were included in a phase III trial, the most common causes for noninclusion were ineligibility due to advanced age or the presence of significant comorbidity [<a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/102\" class=\"abstract_t\">102</a>].</p><p/><p>Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (<a href=\"http://www.clinicaltrials.gov/&amp;token=NK91I08KOJ1eJ1hT1o/oHgJu4vbbEBRl2V0d48fIIMDpbZTpeZvuNaOE2M5VxYDS&amp;TOPIC_ID=4530\" target=\"_blank\" class=\"external\">www.clinicaltrials.gov</a>).</p><p class=\"headingAnchor\" id=\"H2612455684\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-acute-myeloid-leukemia\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Acute myeloid leukemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=acute-myeloid-leukemia-aml-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Acute myeloid leukemia (AML) (The Basics)&quot;</a> and <a href=\"topic.htm?path=leukemia-in-adults-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Leukemia in adults (The Basics)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=acute-myeloid-leukemia-aml-treatment-in-adults-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H29\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Management of acute myeloid leukemia (AML) in older adults (&ge;60 years old) differs from treatment of AML in younger patients. (See <a href=\"#H266976324\" class=\"local\">'Distinctive aspects of AML in older adults'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Goals of care and selection of initial therapy for older patients with AML are influenced by the patient's medical fitness, prognostic features of the AML cells, age, and individual preferences. (See <a href=\"#H1487970949\" class=\"local\">'Goals of care'</a> above and <a href=\"#H1564444133\" class=\"local\">'Selection of initial therapy'</a> above.)</p><p/><p class=\"bulletIndent1\">Age alone does not determine whether the goal is cure versus palliation. Whether the goal is cure or palliation, treatment of older patients with AML can prolong and improve the quality of life. (See <a href=\"#H1951896920\" class=\"local\">'Benefits of treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Based on an assessment of medical fitness, we classify older patients as one of the following (see <a href=\"#H1564444133\" class=\"local\">'Selection of initial therapy'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Medically fit</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Intermediate fitness</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Medically frail</p><p/><p class=\"bulletIndent1\">Within these categories of medical fitness, treatment decisions are influenced by prognostic (ie, cytogenetic and molecular) features of the leukemic cells (<a href=\"image.htm?imageKey=HEME%2F111588\" class=\"graphic graphic_table graphicRef111588 \">table 3</a>), personal preferences, and goals of care. We favor participation in a clinical trial, when available.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For medically fit older adults, selection of treatment is based on the prognostic features of the AML cells, as follows:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For favorable or intermediate prognosis AML, we suggest remission induction treatment with infusional <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> and <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a> (&quot;7+3&quot; therapy) rather than alternative remission induction chemotherapy regimens, lower intensity therapies, or supportive care alone&nbsp;(<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). (See <a href=\"#H3116630272\" class=\"local\">'Medically fit patients with favorable/intermediate prognosis AML'</a> above.)</p><p/><p class=\"bulletIndent2\">An acceptable alternative to 7+3 therapy is treatment with CPX-351 (a liposomal formulation of <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a> and <a href=\"topic.htm?path=daunorubicin-drug-information\" class=\"drug drug_general\">daunorubicin</a> in a fixed 5:1 molar ratio), as described above. (See <a href=\"#H3825144930\" class=\"local\">'CPX-351 (liposomal cytarabine/daunorubicin)'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For adverse prognosis AML, we suggest treatment with CPX-351 or a hypomethylating agent (eg, <a href=\"topic.htm?path=decitabine-drug-information\" class=\"drug drug_general\">decitabine</a>, <a href=\"topic.htm?path=azacitidine-drug-information\" class=\"drug drug_general\">azacitidine</a>) rather than 7+3 therapy, alternative remission induction regimens, other lower intensity treatments, or supportive care alone (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H2867001021\" class=\"local\">'Medically fit patients with adverse features of AML'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients of intermediate medical fitness, our approach is based on the patient's functional status, AML prognostic features, and personal preferences. Options for treatment include remission induction therapy, lower intensity agents, and supportive care. (See <a href=\"#H723416755\" class=\"local\">'Intermediate medical fitness'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For medically frail patients, treatment is focused primarily on relief of symptoms, prolongation of life, and improving quality of life. Options include treatment with lower intensity therapy or supportive care alone. (See <a href=\"#H1940102133\" class=\"local\">'Selection of lower intensity treatments'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>After achieving complete remission (CR), long-term survival in older patients with AML is unlikely unless it is followed by consolidation therapy with chemotherapy or allogeneic hematopoietic cell transplantation (HCT). Decisions regarding post-remission management are informed by the patient's general health status and prognostic features of the AML cells. (See <a href=\"#H544958330\" class=\"local\">'Post-remission management'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For medically fit older patients with favorable or intermediate prognosis AML, we suggest chemotherapy with intermediate dose <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a>, rather than high dose cytarabine, other chemotherapy regimens, or allogeneic HCT (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For medically fit older patients with adverse prognosis AML, we offer treatment with reduced intensity or nonmyeloablative allogeneic HCT, generally in the context of a clinical trial.</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/1\" class=\"nounderline abstract_t\">Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica 2012; 97:1916.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/2\" class=\"nounderline abstract_t\">Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113:4179.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/3\" class=\"nounderline abstract_t\">Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J 2005; 11:449.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/4\" class=\"nounderline abstract_t\">B&uuml;chner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009; 27:61.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/5\" class=\"nounderline abstract_t\">Kantarjian H, O'brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006; 106:1090.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/6\" class=\"nounderline abstract_t\">Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98:1312.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/7\" class=\"nounderline abstract_t\">Cancer and Leukemia Group B 8461, Farag SS, Archer KJ, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006; 108:63.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/8\" class=\"nounderline abstract_t\">Sekeres MA, Stone RM, Zahrieh D, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2004; 18:809.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/9\" class=\"nounderline abstract_t\">Yogaparan T, Panju A, Minden M, et al. Information needs of adult patients 50 or older with newly diagnosed acute myeloid leukemia. Leuk Res 2009; 33:1288.</a></li><li class=\"breakAll\">http://geriatrictoolkit.missouri.edu/SPPB-Score-Tool.pdf (Accessed on October 24, 2017).</li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/11\" class=\"nounderline abstract_t\">Abel GA, Klepin HD. Frailty and the management of hematologic malignancies. Blood 2018; 131:515.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/12\" class=\"nounderline abstract_t\">Rao AV. Fitness in the elderly: how to make decisions regarding acute myeloid leukemia induction. Hematology Am Soc Hematol Educ Program 2016; 2016:339.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/13\" class=\"nounderline abstract_t\">Sekeres MA, Elson P, Kalaycio ME, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood 2009; 113:28.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/14\" class=\"nounderline abstract_t\">L&ouml;wenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989; 7:1268.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/15\" class=\"nounderline abstract_t\">Juliusson G, Swedish AML Group. Most 70- to 79-year-old patients with acute myeloid leukemia do benefit from intensive treatment. Blood 2011; 117:3473.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/16\" class=\"nounderline abstract_t\">Wetzler M, Mr&oacute;zek K, Kohlschmidt J, et al. Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. Haematologica 2014; 99:308.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/17\" class=\"nounderline abstract_t\">Harb AJ, Tan W, Wilding GE, et al. Treating octogenarian and nonagenarian acute myeloid leukemia patients--predictive prognostic models. Cancer 2009; 115:2472.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/18\" class=\"nounderline abstract_t\">Klepin HD. Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly. Clin Geriatr Med 2016; 32:155.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/19\" class=\"nounderline abstract_t\">L&ouml;wenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009; 361:1235.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/20\" class=\"nounderline abstract_t\">Wahlin A, Markev&auml;rn B, Golovleva I, Nilsson M. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol 2001; 115:25.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/21\" class=\"nounderline abstract_t\">Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331:896.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/22\" class=\"nounderline abstract_t\">Pr&eacute;bet T, Boissel N, Reutenauer S, et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol 2009; 27:4747.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/23\" class=\"nounderline abstract_t\">Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010; 28:556.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/24\" class=\"nounderline abstract_t\">Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012; 30:2670.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/25\" class=\"nounderline abstract_t\">Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A 2010; 107:7473.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/26\" class=\"nounderline abstract_t\">L&uuml;bbert M, R&uuml;ter BH, Claus R, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica 2012; 97:393.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/27\" class=\"nounderline abstract_t\">Quint&aacute;s-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 2012; 120:4840.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/28\" class=\"nounderline abstract_t\">Welch JS, Petti AA, Miller CA, et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med 2016; 375:2023.</a></li><li class=\"breakAll\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf (Accessed on February 01, 2018).</li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/30\" class=\"nounderline abstract_t\">Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 2010; 116:4422.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/31\" class=\"nounderline abstract_t\">Wang ES. Treating acute myeloid leukemia in older adults. Hematology Am Soc Hematol Educ Program 2014; 2014:14.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/32\" class=\"nounderline abstract_t\">Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004; 103:479.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/33\" class=\"nounderline abstract_t\">L&ouml;wenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998; 16:872.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/34\" class=\"nounderline abstract_t\">Dillman RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood 1991; 78:2520.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/35\" class=\"nounderline abstract_t\">Burnett AK, Milligan D, Goldstone A, et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol 2009; 145:318.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/36\" class=\"nounderline abstract_t\">Gurion R, Belnik-Plitman Y, Gafter-Gvili A, et al. Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. Cochrane Database Syst Rev 2012; :CD008238.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/37\" class=\"nounderline abstract_t\">Stone RM, Berg DT, George SL, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 2001; 98:548.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/38\" class=\"nounderline abstract_t\">Uyl-de Groot CA, L&ouml;wenberg B, Vellenga E, et al. Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. Br J Haematol 1998; 100:629.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/39\" class=\"nounderline abstract_t\">Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995; 332:1671.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/40\" class=\"nounderline abstract_t\">Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98:1302.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/41\" class=\"nounderline abstract_t\">Godwin JE, Kopecky KJ, Head DR, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 1998; 91:3607.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/42\" class=\"nounderline abstract_t\">Amadori S, Suciu S, Jehn U, et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 2005; 106:27.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/43\" class=\"nounderline abstract_t\">Godwin CD, Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia 2017; 31:1855.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/44\" class=\"nounderline abstract_t\">Amadori S, Suciu S, Selleslag D, et al. Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol 2016; 34:972.</a></li><li class=\"breakAll\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761060lbl.pdf.</li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/46\" class=\"nounderline abstract_t\">Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010; 28:2389.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/47\" class=\"nounderline abstract_t\">Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010; 28:549.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/48\" class=\"nounderline abstract_t\">Burnett AK, Russell NH, Hunter AE, et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 2013; 122:1384.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/49\" class=\"nounderline abstract_t\">Burnett AK, Russell NH, Hills RK, et al. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia. Leukemia 2017; 31:310.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/50\" class=\"nounderline abstract_t\">Ferrara F, Annunziata M, Copia C, et al. Therapeutic options and treatment results for patients over 75 years of age with acute myeloid leukemia. Haematologica 1998; 83:126.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/51\" class=\"nounderline abstract_t\">Leoni F, Ciolli S, Nozzoli C, et al. Idarubicin in induction treatment of acute myeloid leukemia in the elderly. Haematologica 1997; 82:13.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/52\" class=\"nounderline abstract_t\">Juliusson G, H&ouml;glund M, Karlsson K, et al. Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. Br J Haematol 2003; 123:810.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/53\" class=\"nounderline abstract_t\">Letendre L, Noel P, Litzow MR, et al. Treatment of acute myelogenous leukemia in the older patient with attenuated high-dose ara-C. Am J Clin Oncol 1998; 21:142.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/54\" class=\"nounderline abstract_t\">Manoharan A, Baker RI, Kyle PW. Low-dose combination chemotherapy for acute myeloid leukemia in elderly patients: a novel approach. Am J Hematol 1997; 55:115.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/55\" class=\"nounderline abstract_t\">Feldman EJ, Seiter K, Damon L, et al. A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia 1997; 11:485.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/56\" class=\"nounderline abstract_t\">Stein RS, Vogler WR, Winton EF, et al. Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial. Leuk Res 1990; 14:895.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/57\" class=\"nounderline abstract_t\">Estey EH, Thall PF, Giles FJ, et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002; 99:4343.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/58\" class=\"nounderline abstract_t\">Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 2002; 100:3869.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/59\" class=\"nounderline abstract_t\">Giles FJ, Kantarjian HM, Cortes JE, et al. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol 2003; 21:1722.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/60\" class=\"nounderline abstract_t\">Ossenkoppele GJ, Graveland WJ, Sonneveld P, et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood 2004; 103:2908.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/61\" class=\"nounderline abstract_t\">Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006; 108:45.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/62\" class=\"nounderline abstract_t\">Sudan N, Rossetti JM, Shadduck RK, et al. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer 2006; 107:1839.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/63\" class=\"nounderline abstract_t\">Giles F, Rizzieri D, Karp J, et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol 2007; 25:25.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/64\" class=\"nounderline abstract_t\">Lancet JE, Gojo I, Gotlib J, et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 2007; 109:1387.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/65\" class=\"nounderline abstract_t\">Clavio M, Vignolo L, Albarello A, et al. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. Br J Haematol 2007; 138:186.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/66\" class=\"nounderline abstract_t\">Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007; 110:2302.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/67\" class=\"nounderline abstract_t\">Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008; 112:1638.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/68\" class=\"nounderline abstract_t\">Baer MR, George SL, Caligiuri MA, et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol 2008; 26:4934.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/69\" class=\"nounderline abstract_t\">Harousseau JL, Martinelli G, Jedrzejczak WW, et al. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood 2009; 114:1166.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/70\" class=\"nounderline abstract_t\">Fenaux P, Mufti GJ, Hellstr&ouml;m-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28:562.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/71\" class=\"nounderline abstract_t\">Agura E, Cooper B, Holmes H, et al. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. Oncologist 2011; 16:197.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/72\" class=\"nounderline abstract_t\">Baer MR, George SL, Sanford BL, et al. Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia 2011; 25:800.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/73\" class=\"nounderline abstract_t\">Maurillo L, Venditti A, Spagnoli A, et al. Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program. Cancer 2012; 118:1014.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/74\" class=\"nounderline abstract_t\">Kim H, Lee JH, Joo YD, et al. A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60&nbsp;yr with resistant acute myeloid leukemia: a comparison with intensive younger patients' trial. Eur J Haematol 2016; 96:188.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/75\" class=\"nounderline abstract_t\">Ramsingh G, Westervelt P, McBride A, et al. Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML. Int J Hematol 2014; 99:272.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/76\" class=\"nounderline abstract_t\">Garcia-Manero G, Tambaro FP, Bekele NB, et al. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol 2012; 30:2204.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/77\" class=\"nounderline abstract_t\">Attar EC, Johnson JL, Amrein PC, et al. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol 2013; 31:923.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/78\" class=\"nounderline abstract_t\">Sekeres MA, Gundacker H, Lancet J, et al. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood 2011; 118:523.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/79\" class=\"nounderline abstract_t\">Chauncey TR, Gundacker H, Shadman M, et al. Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. Br J Haematol 2010; 148:48.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/80\" class=\"nounderline abstract_t\">Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002; 100:1224.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/81\" class=\"nounderline abstract_t\">Al-Ali HK, Jaekel N, Junghanss C, et al. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma 2012; 53:110.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/82\" class=\"nounderline abstract_t\">Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 2011; 29:2521.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/83\" class=\"nounderline abstract_t\">Fenaux P, Gattermann N, Seymour JF, et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol 2010; 149:244.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/84\" class=\"nounderline abstract_t\">Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20:2429.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/85\" class=\"nounderline abstract_t\">Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007; 109:1114.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/86\" class=\"nounderline abstract_t\">Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10:223.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/87\" class=\"nounderline abstract_t\">Sadashiv SK, Hilton C, Khan C, et al. Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia. Cancer Med 2014; 3:1570.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/88\" class=\"nounderline abstract_t\">Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts. Blood 2015; 126:291.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/89\" class=\"nounderline abstract_t\">DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 2018; 19:216.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/90\" class=\"nounderline abstract_t\">Bhatnagar B, Duong VH, Gourdin TS, et al. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy. Leuk Lymphoma 2014; 55:1533.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/91\" class=\"nounderline abstract_t\">Ritchie EK, Feldman EJ, Christos PJ, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk Lymphoma 2013; 54:2003.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/92\" class=\"nounderline abstract_t\">Issa JP, Garcia-Manero G, Huang X, et al. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer 2015; 121:556.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/93\" class=\"nounderline abstract_t\">Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1990; 8:272.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/94\" class=\"nounderline abstract_t\">Farag SS, Maharry K, Zhang MJ, et al. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 2011; 17:1796.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/95\" class=\"nounderline abstract_t\">Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007; 109:5129.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/96\" class=\"nounderline abstract_t\">McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010; 28:1878.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/97\" class=\"nounderline abstract_t\">Pratz KW, Levis M. How I treat FLT3-mutated AML. Blood 2017; 129:565.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/98\" class=\"nounderline abstract_t\">Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 2017; 130:722.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/99\" class=\"nounderline abstract_t\">van der Helm LH, Scheepers ER, Veeger NJ, et al. Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients. J Hematol Oncol 2013; 6:29.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/100\" class=\"nounderline abstract_t\">Gupta N, Miller A, Gandhi S, et al. Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients &ge;60 years old. Am J Hematol 2015; 90:639.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/101\" class=\"nounderline abstract_t\">Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061.</a></li><li><a href=\"https://www.uptodate.com/contents/acute-myeloid-leukemia-treatment-and-outcomes-in-older-adults/abstract/102\" class=\"nounderline abstract_t\">Mengis C, Aebi S, Tobler A, et al. Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. J Clin Oncol 2003; 21:3933.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4530 Version 49.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H29\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H3665949846\" id=\"outline-link-H3665949846\">DEFINITIONS</a></li><li><a href=\"#H266976324\" id=\"outline-link-H266976324\">DISTINCTIVE ASPECTS OF AML IN OLDER ADULTS</a></li><li><a href=\"#H1487970949\" id=\"outline-link-H1487970949\">GOALS OF CARE</a></li><li><a href=\"#H2593273779\" id=\"outline-link-H2593273779\">DETERMINATION OF MEDICAL FITNESS</a></li><li><a href=\"#H1687713850\" id=\"outline-link-H1687713850\">OUR APPROACH TO INITIAL THERAPY</a><ul><li><a href=\"#H2191324414\" id=\"outline-link-H2191324414\">Emergency management</a><ul><li><a href=\"#H3009555264\" id=\"outline-link-H3009555264\">- Acute promyelocytic leukemia</a></li></ul></li><li><a href=\"#H629514296\" id=\"outline-link-H629514296\">Timing of initial therapy</a></li><li><a href=\"#H1951896920\" id=\"outline-link-H1951896920\">Benefits of treatment</a></li><li><a href=\"#H1564444133\" id=\"outline-link-H1564444133\">Selection of initial therapy</a><ul><li><a href=\"#H3116630272\" id=\"outline-link-H3116630272\">- Medically fit patients with favorable/intermediate prognosis AML</a></li><li><a href=\"#H2867001021\" id=\"outline-link-H2867001021\">- Medically fit patients with adverse features of AML</a></li><li><a href=\"#H723416755\" id=\"outline-link-H723416755\">- Intermediate medical fitness</a></li><li><a href=\"#H369343491\" id=\"outline-link-H369343491\">- Medically frail patients</a></li></ul></li></ul></li><li><a href=\"#H2721395459\" id=\"outline-link-H2721395459\">INITIAL TREATMENT</a><ul><li><a href=\"#H3395673025\" id=\"outline-link-H3395673025\">Intensive remission induction (7+3 therapy)</a></li><li><a href=\"#H3825144930\" id=\"outline-link-H3825144930\">CPX-351 (liposomal cytarabine/daunorubicin)</a></li><li><a href=\"#H3298933996\" id=\"outline-link-H3298933996\">Alternative remission induction approaches</a><ul><li><a href=\"#H65465221\" id=\"outline-link-H65465221\">- Gemtuzumab ozogamicin</a></li><li><a href=\"#H1138846737\" id=\"outline-link-H1138846737\">- Clofarabine and other regimens</a></li></ul></li><li><a href=\"#H2001081868\" id=\"outline-link-H2001081868\">Lower intensity treatments</a><ul><li><a href=\"#H1940102133\" id=\"outline-link-H1940102133\">- Selection of lower intensity treatments</a><ul><li><a href=\"#H3562734933\" id=\"outline-link-H3562734933\">Azacitidine</a></li><li><a href=\"#H766270955\" id=\"outline-link-H766270955\">Decitabine</a></li><li><a href=\"#H1002009560\" id=\"outline-link-H1002009560\">Low dose cytarabine</a></li></ul></li></ul></li><li><a href=\"#H2623334727\" id=\"outline-link-H2623334727\">Supportive care</a></li></ul></li><li><a href=\"#H219716188\" id=\"outline-link-H219716188\">RESPONSE EVALUATION</a></li><li><a href=\"#H544958330\" id=\"outline-link-H544958330\">POST-REMISSION MANAGEMENT</a><ul><li><a href=\"#H2828774744\" id=\"outline-link-H2828774744\">Selection of post-remission therapy</a><ul><li><a href=\"#H43344244\" id=\"outline-link-H43344244\">- Consolidation chemotherapy</a></li><li><a href=\"#H3827308373\" id=\"outline-link-H3827308373\">- Hematopoietic cell transplantation (HCT)</a></li><li><a href=\"#H2621482413\" id=\"outline-link-H2621482413\">- Maintenance therapy</a></li></ul></li></ul></li><li><a href=\"#H1516878732\" id=\"outline-link-H1516878732\">RELAPSED OR RESISTANT AML</a></li><li><a href=\"#H513801755\" id=\"outline-link-H513801755\">TREATMENT OUTCOMES</a><ul><li><a href=\"#H361018781\" id=\"outline-link-H361018781\">Treatment versus supportive care alone</a></li><li><a href=\"#H3153621328\" id=\"outline-link-H3153621328\">Intensive treatment versus hypomethylating agents</a></li></ul></li><li><a href=\"#H27\" id=\"outline-link-H27\">CLINICAL TRIALS</a></li><li><a href=\"#H2612455684\" id=\"outline-link-H2612455684\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H29040892\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H29\" id=\"outline-link-H29\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"HEME/4530|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/72901\" class=\"graphic graphic_table\">- ECOG performance scale</a></li><li><a href=\"image.htm?imageKey=HEME/65323\" class=\"graphic graphic_table\">- Modified CCI</a></li><li><a href=\"image.htm?imageKey=HEME/111588\" class=\"graphic graphic_table\">- 2017 ELN risk stratification of AML by genetics</a></li><li><a href=\"image.htm?imageKey=HEME/59272\" class=\"graphic graphic_table\">- HCT-CI and CCI</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-acute-myeloid-leukemia\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-acute-promyelocytic-leukemia-in-adults\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=determining-eligibility-for-allogeneic-hematopoietic-cell-transplantation\" class=\"medical medical_review\">Determining eligibility for allogeneic hematopoietic cell transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hyperleukocytosis-and-leukostasis-in-hematologic-malignancies\" class=\"medical medical_review\">Hyperleukocytosis and leukostasis in hematologic malignancies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=induction-therapy-for-acute-myeloid-leukemia-in-younger-adults\" class=\"medical medical_review\">Induction therapy for acute myeloid leukemia in younger adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-treatment-of-acute-promyelocytic-leukemia-in-adults\" class=\"medical medical_review\">Initial treatment of acute promyelocytic leukemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-acute-myeloid-leukemia-in-adults\" class=\"medical medical_review\">Overview of acute myeloid leukemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-complications-of-acute-myeloid-leukemia\" class=\"medical medical_review\">Overview of the complications of acute myeloid leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=acute-myeloid-leukemia-aml-the-basics\" class=\"medical medical_basics\">Patient education: Acute myeloid leukemia (AML) (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=acute-myeloid-leukemia-aml-treatment-in-adults-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=leukemia-in-adults-the-basics\" class=\"medical medical_basics\">Patient education: Leukemia in adults (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=post-remission-therapy-for-acute-myeloid-leukemia-in-younger-adults\" class=\"medical medical_review\">Post-remission therapy for acute myeloid leukemia in younger adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pretreatment-evaluation-and-prognosis-of-acute-myeloid-leukemia-in-older-adults\" class=\"medical medical_review\">Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prognosis-of-acute-myeloid-leukemia\" class=\"medical medical_review\">Prognosis of acute myeloid leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=remission-criteria-in-acute-myeloid-leukemia-and-monitoring-for-residual-disease\" class=\"medical medical_review\">Remission criteria in acute myeloid leukemia and monitoring for residual disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-acute-myeloid-leukemia\" class=\"medical medical_society_guidelines\">Society guideline links: Acute myeloid leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-chemotherapy-for-cancer-in-elderly-persons\" class=\"medical medical_review\">Systemic chemotherapy for cancer in elderly persons</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=therapy-related-myeloid-neoplasms-acute-myeloid-leukemia-and-myelodysplastic-syndrome\" class=\"medical medical_review\">Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-acute-myeloid-leukemia\" class=\"medical medical_review\">Treatment of relapsed or refractory acute myeloid leukemia</a></li></ul></div></div>","javascript":null}